Paclitaxel

Premium, highly purified excipients for demanding parenteral applications and a new U.S. PEG manufacturing site to strengthen North and Latin American supply chains.

FDA accepted an sBLA for adjuvant PD‑L1 therapy plus chemotherapy in stage III dMMR/MSI‑H colon cancer; agency decision expected Oct 9, 2026.

TroFuse‑005 (776 pts) showed significant OS and PFS improvement vs chemotherapy in advanced/recurrent endometrial cancer after platinum and anti‑PD‑1/PD‑L1 therapy; ORR met; safety consistent.

Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16

KEYTRUDA plus paclitaxel improves overall survival in platinum-resistant ovarian cancer, regardless of PD-L1 status, as shown in the KEYNOTE-B96 trial.